Outcome of adult T-lymphoblastic lymphoma after acute lymphoblastic leukemia-type treatment: A GOELAMS trial

Haematologica

Volumn 92, Issue 12, 2007, Pages 1623-1630

  Hunault, Mathilde ^a   Truchan Graczyk, Malgorzata ^a   Caillot, Denis ^b   Harousseau, Jean Luc ^c   Bologna, Serge ^d   Himberlin, Chantal ^e   Guyotat, Denis ^f   Berthou, Christian ^g   Casassus, Philippe ^h   Baranger, Laurence ⁱ   Béné, Marie Christine ^j   Ifrah, Norbert ^a   Gyan, Emmanuel ^k,l  

^a Haematology Department   (France)

^b Haematology Department   (France)

^c Haematology Department of Nantes   (France)

^d Haematology Department   (France)

^e Haematology Department   (France)

^f Haematology Department   (France)

^g Haematology Department   (France)

^h Haematology Department   (France)

ⁱ Cytogenetics Department   (France)

^j Immunology Department   (France)

^k Haematology Department   (France)

^l CHU BRETONNEAU   (France)

more..

Author keywords

Autologous bone marrow transplantation; Lymphoblastic acute leukemia; Lymphoblastic lymphoma

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; FOLINIC ACID; IDARUBICIN; MERCAPTOPURINE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; PREDNISONE; STEROID; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG MEGADOSE; FEMALE; HUMAN; LEUKOCYTOSIS; LYMPHOBLASTOMA; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSIS; RELAPSE; REMISSION; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TREATMENT DURATION;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REMISSION INDUCTION; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS;

EID: 37049005585     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.10882     Document Type: Article

References (26)

1. Soslow RA, Baergen RN, Warnke RA. B-lineage lymphoblastic lymphoma is a clinicopathologic entity distinct from other histologically similar aggressive lymphomas with blastic morphology. Cancer 1999; 85:2648-54.
2. Hoelzer D, Gokbuget N. Treatment of lymphoblastic lymphoma in adults. Best Pract Res Clin Haematol 2002;15:713-28.
3. Morel P, Lepage E, Brice P, Dupriez B, D'Agay MF, Fenaux P, et al. Prognosis and treatment of lymphoblastic lymphoma in adults: a report on 80 patients. J Clin Oncol 1992;10:1078-85.
4. Bouabdallah R, Xerri L, Bardou VJ, Stoppa AM, Blaise D, Sainty D, et al. Role of induction chemotherapy and bone marrow transplantation in adult lymphoblastic lymphoma: a report on 62 patients from a single center. Ann Oncol 1998;9:619-25.
5. Le Gouill S, Lepretre S, Briere J, Morel P, Bouabdallah R, Raffoux E, et al. Adult lymphoblastic lymphoma: a retrospective analysis of 92 patients under 61 years included in the LNH87/93 trials. Leukemia 2003;17:2220-4.
6. Reiter A, Schrappe M, Ludwig WD, Tiemann M, Parwaresch R, Zimmermann M, et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood. 2000;95:416-21.
7. Hoelzer D, Gokbuget N, Digel W, Faak T, Kneba M, Reutzel R, et al. Outcome of adult patients witli T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia. Blood 2002; 99:4379-85.
8. Dabaja BS, Ha CS, Thomas DA, Wilder RB, Gopal R, Cortes J, et al. The role of local radiation therapy for mediastinal disease in adults with T-cell lymphoblastic lymphoma. Cancer 2002;94:2738-44.
9. Hoelzer D, Thiel E, Loffler H, Buchner T, Ganser A, Heil G, et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 1988;71:123-31.
10. Hunault M, Harousseau JL, Delain M, Truchan-Graczyk M, Cahn JY, Witz F, et al. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. Blood 2004;104:3028-37.
11. Sweetenham JW, Santini G, Qian W, Guelfi M, Schmitz N, Simnett S, et al. High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group. J Clin Oncol 2001;19:2927-36.
12. Thomas DA, O'Brien S, Cortes J, Giles FJ, Faderl S, Verstovsek S, et al. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood 2004;104:1624-30.
13. Coleman CN, Cohen JR, Burke JS, Rosenberg SA. Lymphoblastic lymphoma in adults: results of a pilot protocol. Blood 1981;57:679-84.
14. Colgan JP, Andersen J, Habermann TM, Earle JD, O'Connell MJ, Neiman RS, et al. Long-term follow-up of a CHOP-based regimen with maintenance therapy and central nervous system prophylaxis in lymphoblastic non-Hodgkin's lymphoma. Leuk Lymphoma 1994; 15:291-6.
15. Thomas DA, Kantarjian HM. Lymphoblastic lymphoma. Hematol Oncol Clin North Am 2001;15:51-95.
16. Slater DE, Mertelsmann R, Koziner B, Higgins C, McKenzie S, Schauer P, et al. Lymphoblastic lymphoma in adults. J Clin Oncol 1986;4:57-67.
17. Zinzani PL, Bendandi M, Visani G, Gherlinzoni F, Frezza G, Merla E, et al. Adult lymphoblastic lymphoma: clinical features and prognostic factors in 53 patients. Leuk Lymphoma 1996;23:577-82.
18. Liang R, Todd D, Chan TK, Chiu E, Lie A, Ho FC, et al. Intensive chemotherapy for adult lymphoblastic lymphomas. Cancer Chemother Pharmacol 1991;29:80-2.
19. Kaiser U, Uebelacker I, Havemann K. Non-Hodgkin's lymphoma protocols in the treatment of patients with Burkitt's lymphoma and lymphoblastic lymphoma: a report on 58 patients. Leuk Lymphoma 1999;36:101-8.
20. Milpied N, Ifrah N, Kuentz M, Maraninchi D, Colombat P, Blaise D, et al. Bone marrow transplantation for adult poor prognosis lymphoblastic lymphoma in first complete remission. Br J Haematol 1989;73:82-7.
21. Voakes JB, Jones SE, McKelvey EM. The chemotherapy of lymphoblastic lymphoma. Blood 1981;57:186-8.
22. Levine JE, Harris RE, Loberiza FR Jr, Armitage JO, Vose JM, Van Besien K, et al. A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood 2003;101:2476-82.
23. Peniket AJ, Ruiz de Elvira MC, Taghipour G, Cordonnier C, Gluckman E, de Witte T, et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 2003;31:667-78.
24. Jost LM, Jacky E, Dommann-Scherrer C, Honegger HP, Maurer R, Sauter C, et al. Short-term weekly chemotherapy followed by high-dose therapy with autologous bone marrow transplantation for lymphoblastic and Burkitt's lymphomas in adult patients. Ann Oncol 1995; 6:445-51.
25. van Imhoff GW, van der Holt B, MacKenzie MA, Ossenkoppele GJ, Wijermans PW, Kramer MH, et al. Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma. Leukemia 2005;19:945-52.
26. Jabbour E, Koscielny S, Sebban C, Peslin N, Patte C, Gargi T, et al. High survival rate with the LMT-89 regimen in lymphoblastic lymphoma (LL), but not in T-cell acute lymphoblastic leukemia (T-ALL). Leukemia 2006;20:814-9.